PURPOSE: To evaluate the efficacy and safety of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA) in patients with chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL) and to compare its efficacy to the patients' last qualifying …

For the dosimetric step, 450 mg of tositumomab in 50 mL of 0.9% sodium chloride is infused intravenously over 60 minutes. This is followed by 35 mg 5 mCi (185 MBq) of iodine 131 tositumomab in 30 mL of 0.9% sodium chloride over 20 minutes. Total body gamma camera counts and whole body images are obtained at 1 hour and before urination.

Iodine I 131/ tositumomab is used for: Treating certain forms of non-Hodgkin lymphoma in patients who have not responded to other therapy. Iodine I 131/tositumomab is a …

CASE 4: Patient diagnosed with Hodgkin's granuloma of intra-abdominal lymph nodes and spleen underwent outpatient radiopharmaceutical therapy via intravenous administration of therapeutic iodine I-131 tositumomab radiopharmaceutical therapy, one treatment dose. Which ICD-10-CM code is reported for the first-listed diagnosis? a. C81.73 b. C81.98

46 Iodine I 131 Tositumomab 47 Iodine I 131 Tositumomab is a radio -iodinated derivat ive of Tositumomab 48 that has been covalently linked to Iodine-131. Unbound radio-iodine and 49 other reactants have been removed by chromatographic purification steps. 50 Iodine I 131 Tositumomab is supplied as a sterile, clear, preservative -free

Iodine-131 tositumomab represents one of the most active single agents for the treatment of recurrent indolent and transformed B-cell non-Hodgkin's lymphoma, as demonstrated by several clinical trials summarized in this review. Tositumomab is an immunoglobulin G murine monoclonal antibody that binds to the CD20 antigen on the …

Tositumomab I 131. The Bexxar (tositumomab and iodine plus 131I-tositumomab) regimen consists of the sequential administration of a dose of the unlabeled murine Mab tositumomab to optimize biodistribution and increase tumor localization443,444 of the 131I-tositumomab that is administered thereafter.

Tositumomab I 131 is no longer marketed in the US. Information in this record refers to the use of tositumomab I 131 as a therapeutic agent. No information is available on the use of tositumomab I 131 during breastfeeding. Because of the potential for serious adverse reactions in nursing infants, the manufacturer and expert opinion …

131I-Tositumomab (131I-B1 MAb) is a conjugation of 131I with a murine anti-CD20 monoclonal antibody (MAb) that can be used for both imaging and therapy of lymphoid malignancies (1-8). It was …

Tositumomab and iodine I 131 tositumomab (Bexxar® Therapeutic Regimen) has been found effective in relapsed/refractory follicular lymphoma. We now report updated results of a single center, single-arm, Phase II trial of a single one-week course of this treatment for 76 previously untreated, stage III and IV, follicular lymphoma …

Iodine 131 tositumomab (131 I-TST) is a murine monoclonal antibody against the CD20 cell surface protein and is directly covalently conjugated to 131 I, a radioactive β and γ emitter. While initially approved for use in relapsed, refractory, or transformed low grade B-cell NHL, investigational uses with promising results include …

The drug tositumomab and iodine I 131 tositumomab is used to treat cancer. It is a combination of tositumomab, a special type of antibody used to treat cancer, and …

Tositumomab and 131I-tositumomab constitute a relatively new radioimmunotherapeutic regimen for patients with CD20+ follicular non-Hodgkin's lymphoma (NHL). Currently, it is approved for use in patients whose disease has relapsed after chemotherapy and is refactory to rituximab, including patients whose tumors have …

Bexxar is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with CD20­-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed after treatment with rituximab. Bexxar is also referred to by its drug name, tositumomab and iodine I 131 tositumomab.

Iodine-131 5 mCi, tositumomab 35 mg IV over 20 minutes; Allows for individualized dosing. Nonradioactive tositumomab administered via IV injection followed by trace amount of radioactive I-131 to evaluate clearance of radiation from patient. Gamma scan is performed immediately following and at two and four days following dosimetric dose.

Tositumomab is a murine IgG2a monoclonal antibody that selectively binds to CD20 on the surface of normal and malignant B cells. It can be labeled with iodine-131 to yield 131 I-labeled ...

Bexxar is injected into a vein through an IV. You will receive two different injections (tositumomab, and iodine I-131 tositumomab) given one at a time. The first injection is given over at least 60 minutes and the second injection is given over at least 20 minutes. Bexxar treatment is usually given in two steps over a span of 7 days.

A single course of iodine I 131 tositumomab was significantly more efficacious than the LQC received by extensively pretreated patients with chemotherapy-refractory, low-grade, or transformed low- grade non-Hodgkin's lymphoma and had an acceptable safety profile. PURPOSE To evaluate the efficacy and safety of …

STANFORD, California-Seventy percent of low-grade and transformed low-grade non-Hodgkin's lymphoma (NHL) patients respond to the drug iodine I 131 tositumomab (Bexxar) even though progressing after rituximab (Rituxan). A study of 40 patients who had previously failed to respond or progressed on rituximab, also showed that 40% had a …

Tositumomab is an IgG2a murine anti-CD20 monoclonal antibody. 3 In vitro, the binding of tositumomab to CD20-positive cells invoked antibody-dependent cellular cytotoxicity, 11 complement-dependent cytotoxicity, 12 and apoptosis. 13 Conjugation of tositumomab to a radionuclide such as iodine 131 (131 I) affords irradiation of …

Tositumomab and iodine I 131 tositumomab (Bexxar® Therapeutic Regimen) has been found effective in relapsed/refractory follicular lymphoma. We now report updated results of a single center, single-arm, Phase II trial of a single one-week …

131 I-Tositumomab ( 131 I-B1 MAb) is a conjugation of 131 I with a murine anti-CD20 monoclonal antibody (MAb) that can be used for both imaging and therapy of lymphoid malignancies ( 1-8 ).

Long-term, 5 patients developed elevated thyroid-stimulating hormone levels, 5 were diagnosed with myelodysplasia and 3 with solid tumors. A single, well-tolerated treatment with iodine (131)I tositumomab can, therefore, produce frequent and durable responses in NHL, especially low-grade or transformed NHL. (Blood. …

Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab. Authors: Sandra J. Horning, Anas …

The drug tositumomab and iodine I 131 tositumomab is used to treat cancer. It is a combination of tositumomab, a special type of antibody used to treat cancer, and iodine I 131, a radioactive element that has been shown to be effective against cancer. This drug is given intravenously (IV). Allergic reactions

Tositumomab is the combination of a monoclonal antibody to CD20 and iodine-131 which is used to treat refractory, advanced non-Hodgkin lymphoma. Tositumomab has not been associated with significant serum enzyme elevations during therapy or to cases of idiosyncratic, clinically apparent liver injury. However, …

Iodine I 131 Tositumomab final drug product will be manufactured, labeled, packaged, and distributed by -----. In accordance with approved labeling, your product will bear the proprietary name Bexxarâ and will be marketed as two separate components. The dosimetric component will contain one 35 mg single-use vial and two 225 mg single-use …

Tositumomab (also known as Bexxar; by GlaxoSmithKline) is an 131 -Iodine-labeled murine monoclonal antibody that was approved for use in non-Hodgkin's lymphoma in 2003 [29]. The radiolabeled ...

B1 or Tositumomab was the first B-cell specific antibody to be discovered and it targets the CD20 antigen. The potential therapeutic importance of this discovery in targeting CD20, however remained unrealised until the mid 1990's when Tositumomab was radiolabelled and the 131 I Tositumomab radioimmunotherapy (RIT) regimen (Bexxar™) …

CONCLUSION: A single course of iodine I 131 tositumomab was significantly more efficacious than the LQC received by extensively pretreated patients with …